Dr. Leblond Discusses Treatment After Relapse in CLL

Veronique Leblond, MD
Published: Tuesday, May 02, 2017



Veronique Leblond, MD, head of the Department of Hematology, Pitié Salpêtrière Hospital, Paris, France, discusses the treatment of patients with chronic lymphocytic leukemia (CLL) who have relapsed after initial treatment.

For patients who relapse within 3 years after discontinuation of chemotherapy, BCR inhibitors or venetoclax (Venclexta) can be used.

Questions remain for patients who have late relapses, says Leblond. For these patients with relapses 4 or 5 years after initial therapy, BCR inhibitors can be used—but combinations of immunotherapy, chemotherapy, and BCR inhibitors also hold promise.
 


Veronique Leblond, MD, head of the Department of Hematology, Pitié Salpêtrière Hospital, Paris, France, discusses the treatment of patients with chronic lymphocytic leukemia (CLL) who have relapsed after initial treatment.

For patients who relapse within 3 years after discontinuation of chemotherapy, BCR inhibitors or venetoclax (Venclexta) can be used.

Questions remain for patients who have late relapses, says Leblond. For these patients with relapses 4 or 5 years after initial therapy, BCR inhibitors can be used—but combinations of immunotherapy, chemotherapy, and BCR inhibitors also hold promise.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x